Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO) in a research report issued on Saturday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of CO opened at $0.80 on Friday. The stock has a 50 day simple moving average of $0.98 and a 200 day simple moving average of $1.25. Global Cord Blood has a 52-week low of $2.03 and a 52-week high of $5.50. The firm has a market capitalization of $97.24 million, a PE ratio of 1.25 and a beta of 0.16.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.